Our founders and scientists have dedicated their lives to studying the genome and its role in aging and cancer. We believe that aging is a disease and thus can be treated. Our goal is to develop such treatments to significantly prolong healthy lifespan and protect against the many diseases of aging.
Genome protection is our primary area of expertise
The human genome entombs ancient viruses called retroelements that, when awakened, propagate and wreak havoc on our cells. We aim to develop drugs that protect against cancer and age-related diseases by neutralizing the various retroelements that we collectively call the 'retrobiome'.
We have come a long way in our quest
Some of our therapies are already in the clinic, i.e. being tested in humans, while others are still in preclinical stages but rapidly maturing. Our partnerships with top academic institutions provide access to leading scientific and medical experts and create a powerful foundation for rapid hypothesis testing and expedited clinical translation.
Dr. Gudkov is a world-renowned cancer and longevity researcher. He is one of the pioneers in the field of cell senescence, elucidating the role of p53 and interferon in cancer, as well as the importance of the immune system in the clearance of genome-compromised cells. In the past decade, Dr. Gudkov has also focused on studying LINE-1 and other retroelements, and had suggested important insights about the role of retrobiome in genome instability that accompanies cancer and aging.
Additionally, Dr. Gudkov has been developing various aging biomarkers, such as multifactorial frailty indexes for humans and animals. In conjunction with being the CSO of GPI, Dr. Gudkov holds various positions at the Roswell Park Comprehensive Cancer Center where he serves as a Senior Vice President for Basic Research, a Chair of the Department of Cell Stress Biology, and a member of the senior leadership team for National Cancer Institute (NCI) Cancer Center Support Grant. At Roswell Park, Dr. Gudkov is leading the Cell Stress Biology program in DNA damage and repair, photodynamic therapy, thermal and hypoxic stress and immune modulation.
Previously Dr. Gudkov worked at the Lerner Research Institute, Cleveland Clinic Foundation where he served as a chair of the Department of Molecular Genetics and as a professor of biochemistry at Case Western University. He has authored or co-authored over 250 scientific articles and over 50 issued US patents. Dr. Gudkov holds a Ph.D. in Experimental Oncology from the Cancer Research Center and a Doctor of Science (D.Sc.) degree in Molecular Biology from the Moscow State University.
Yakov Kogan, Ph.D., MBA
Dr. Kogan is a seasoned executive with an exemplary track record of business development and fundraising. Prior to leading operations at GPI, Dr. Kogan served as a CEO and director of Cleveland BioLabs (NASDAQ: CBLI) where he had built the company up from its inception to an operation with over 50 full-time employees, while securing upward of $150 million in equity financing at highly attractive valuations. He was also responsible for securing federal and state grants totaling more than $65 million. In his tenure with CBLI, Dr. Kogan played a significant role in establishing operations, hiring senior operations staff and executing the Company's initial public offering on NASDAQ.
Prior to CBLI, Dr. Kogan served as Director for Business Development at Integrated Genomics in Chicago, IL, where he was responsible for commercial sales and expansion of the company's capital base. Dr. Kogan closed several complex international deals and expanded contracts with governmental research laboratories, representing more than one-third of total sales. Prior to his tenure in business development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics and at ThermoGen, Inc. and as Research Associate at the University of Chicago, where he led the execution of several sophisticated genome sequencing projects.
Dr. Kogan holds a Ph.D. degree in Molecular Biology from VNII Genetica, as well as an M.S. degree in Biology from Moscow State University and an MBA from the University of Chicago.
Katerina Andrianova, Ph.D.
Dr. Andrianova possesses over 10 years of experience in clinical and preclinical stages of drug development in biotech and pharmaceutical industries, as well as over 5 years of experience as a lead R&D manager in innovative anticancer drug development projects. Previously, she held positions of Head of Drug Development at Everon Biosciences and OncoTartis. Dr. Andrianova has extensive drug discovery and drug development expertise, having participated in over 20 projects spanning from translational laboratory research to Phase III clinical trials. She holds a PhD in Biochemistry (Neuroscience).
Dr. Hall has spent the last 7 years working in the private sector for Buffalo-based biotech companies focused on understanding and preventing aging. He started work for Everon Biosciences in 2012, immediately after receiving his doctoral degree from the State University of New York at Buffalo. Quickly rising through the company, he became a principal scientist/project leader focused on identifying senolytic compounds and developing diagnostics and therapeutics against senescence-associated macrophages. In 2018 he was recruited to Genome Protection as a project leader focused on the development of anti-aging therapies.
Lioubov Korotchkina, Ph.D.
Dr. Korotchkina began her research career after obtaining her PhD in Biological Sciences (1987) from Moscow State University. In 1991 she accepted the position of Research Associate at Case Western Reserve University focusing on studying mitochondrial functions. In 1995 she joined the faculty at State University of New York at Buffalo continuing mitochondrial research. In 2001 she reached the position of a Research Assistant Professor.
Katerina Leonova, Ph.D.
Dr. Leonova is an affiliate member at Roswell Park Comprehensive Cancer Center. She got her degree from State University of New York at Buffalo in 2012. Her thesis focused on the tumor suppressor p53 and its role in regulating repetitive elements. During her post-doctoral training she focused on senescence and identifying senolytic compounds in conjuction with a biotech in Buffalo, NY. In 2018, she became affiliated with another Buffalo biotech, this time leading a project focused on immunology and anti-aging. She is an author of a number of publications and patents.
Ilya Gitlin, Ph.D.
Dr. Gitlin has completed his doctorate degree in Cell Stress biology from State University of New York at Buffalo in 2018, his thesis work focused on systemic DNA damage as a possible model of accelerated aging. Prior to entry into graduate school he worked in a diagnostics laboratory from 2004-2009 and in 2011 co-founded a diagnostics laboratory in Houston, TX.
Denis had started his career in 2002 as a leader of Medicinal Chemistry Group at Asinex LTD. In 2008 he was promoted to Director of Research and Development where he led design, discovery and preclinical development of novel inhibitors of protein kinases. He had developed a novel class of inhibitors of receptor proteinkinases with exceptionally high permeability through blood-to-brain barrier for the treatment of CNS cancers, especially glioblastoma multiform and brain metastasis of different solid cancers. Denis had also raised 3 million US dollars funding for the support of drug discovery program.
In 2014, Denis joined OncoTartis/Everon Biosciences as the Director of Medicinal Chemistry focused on early drug discovery and development of novel anti-cancer and senolytic compounds with one compound in current phase 1 clinical trials. In 2018, Denis joined Genome Protection as head of Drug Discovery where he is responsible for design and drug discovery of new medicines in the fields of innovative anti-ageing and anti-cancer drugs using modern methods of medicinal chemistry: X-Ray of protein complex, fragment-based drug design, virtual screening/docking.
Denis holds a M.S. degree in chemistry from the Highest Chemistry College of the Russian Academy of Science.
Anatoli Gleiberman, Ph.D.
Director of Histopathlogy
Slavoljub Vujcic, M.Sc.
Ilia Toshkov, Ph.D.
Andrei Purmal, Ph.D.
Dr. Purmal joined GPI in 2019 as Head of CMC to support preclinical drug development, bringing over 15 years in small molecule drug development experience to the team. Dr. Purmal has a broad background in the chemistry of small molecules and biopolymers, analytical development, hit-to-lead optimization and preclinical drug development.
Prior to joining GPI, Dr. Purmal was the vice president of chemistry at CBLI where he led the team to preclinical and clinical production of the drug Entolimod. Prior to that, Dr. Purmal was Vice President of Biochemical Research at V.I. Technologies, where he led a team of scientists developing a chemical process for inactivation of pathogens in human blood products for transfusions.
Before V.I. Technologies, Dr. Purmal worked as a Principal Scientist at Pentose Pharmaceuticals, where he led a team that identified a novel, small molecule DNA-targeted agent for broad spectrum pathogen inactivation. The success of Dr. Purmal's research team led to Pentose being acquired by V.I. Technologies, Inc., which continued to sponsor clinical studies of this program.
Prior to 1997, Dr. Purmal held several senior research academic positions at the University of Vermont, University of Illinois and Moscow State University. Dr. Purmal holds a Ph.D. degree in Chemistry from Moscow State University.
In the many years we have spent developing ways to combat aging and prevent cancer, we have gained several important insights.
In particular, we have accumulated a wealth of knowledge about the role of genetic and epigenetic instability in both cancer and aging, as well as about the importance of the immune system in clearing cells with a damaged genome.
A sizeable part of human genome is comprised of non-coding DNA that harbors ancient viruses. One such virus, LINE-1, remains active to this day. Activation of LINE-1 in cells triggers antiviral defense mechanisms that produce chronic inflammation, a hallmark of aging. Since LINE-1 activity irreversibly damages DNA, cells have developed several strategies to suppress it. However, innate suppression mechanisms weaken with age, so one of our goals is to create therapies to help our body keep retroelements in check.
By developing drugs against retroelements, we aim to effectively silence their activity, preventing the DNA damage and inflammation associated with cancer and age-related diseases.
Learn more about our science from our CSO himself:
Our Founder and CSO, Dr. Andrei Gudkov, at Undoing Aging 2019
"Can we stop aging?" — a TEDx Talk by Dr. Gudkov
We have a diverse therapeutic pipeline in various stages of development: from the clinical stage to in vitro. Our primary target indications are conventional age-related pathologies, as this is meant to provide us with a clear path to FDA approval with simultaneous evaluation of efficacy of our therapies for other aging manifestations.
We are developing therapies in the following areas:
Pharmacological inhibition of intrinsic DNA damage caused by retroelements with the goal of decreasing cancer adaptability, combating aging and prolonging healthy longevity.
Modulation of specific branches of innate immunity for eradication of genome-compromised cells with the goal of extending healthy longevity.
Induction of an immune response directed against cells with active retroelements with the goal of prolonging healthy longevity and reducing risks of age-related diseases.
Whether you are a researcher working on aging, or an investor looking to fund such research, we would love to hear from you! Alternatively, if you would rather hear from us, please fill out the form below and we will contact you.